<DOC>
	<DOCNO>NCT02777567</DOCNO>
	<brief_summary>The objective study assess safety efficacy single agent Tagrisso ( Osimertinib , hereinafter `` study drug '' ) real world set adult patient advance metastatic , epidermal growth factor receptor ( EGFR ) T790M mutation-positive Non-Small Cell Lung Cancer ( NSCLC ) , Who Have Progressed EGFR tyrosine kinase receptor ( TKI ) therapy .</brief_summary>
	<brief_title>KOREA Study ( Korea Osimertinib Real World Evidence Study Assess Safety Efficacy )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Eligible , active study drug treatment accord approve label ; patient locally advanced metastatic , EGFR T790M mutationpositive NSCLC , progress EGFR tyrosine kinase receptor ( TKI ) therapy 2 . Provision sign date write informed consent patient legally acceptable representative 1 . History hypersensitivity excipients study drug drug similar chemical structure class study drug 2 . Pregnancy and/or breast feeding 3 . Current participation interventional trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>